Travere Therapeutics Inc (TVTX)

Jan 31, 2025

Vanguard Group Inc Reduces Stake in Travere Therapeutics Inc - GuruFocus.com

Jan 31, 2025

Jan 30, 2025

Travere Therapeutics (NASDAQ:TVTX) Shares Down 4.3%What's Next? - MarketBeat

Jan 30, 2025

Jan 28, 2025

(TVTX) Technical Data - Stock Traders Daily

Jan 28, 2025

Jan 27, 2025

Wedbush Boosts Earnings Estimates for Travere Therapeutics - Defense World

Jan 27, 2025

Jan 26, 2025

What is Wedbush’s Estimate for TVTX FY2028 Earnings? - Defense World

Jan 26, 2025

Jan 25, 2025

Travere therapeutics CFO sells shares worth $16,383 - MSN

Jan 25, 2025

Jan 25, 2025

Travere therapeutics SVP William Rote sells $47,424 in stock - MSN

Jan 25, 2025

Jan 25, 2025

TVTX Stock Soars to 52-Week High, Reaching $20.36 - MSN

Jan 25, 2025

Jan 24, 2025

Travere therapeutics exec Elizabeth Reed sells common stock for $47,424 - MSN

Jan 24, 2025

Jan 24, 2025

Travere therapeutics chief commercial officer sells $30,002 in stock - MSN

Jan 24, 2025

Jan 24, 2025

Travere therapeutics director Roy Baynes sells $320,000 in stock - MSN

Jan 24, 2025

Jan 24, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Christopher R. Cline Sells 865 Shares - MarketBeat

Jan 24, 2025

Jan 24, 2025

Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Sells 16,000 Shares of Stock - MarketBeat

Jan 24, 2025

Jan 24, 2025

Sandra Calvin Sells 925 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat

Jan 24, 2025

Jan 24, 2025

Eric M. Dube Sells 10,736 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat

Jan 24, 2025

Jan 24, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells $30,000.96 in Stock - MarketBeat

Jan 24, 2025

Jan 24, 2025

Travere therapeutics CEO Eric Dube sells shares for $208,922 - MSN

Jan 24, 2025

Jan 24, 2025

Travere Therapeutics (NASDAQ:TVTX) Sets New 1-Year HighWhat's Next? - MarketBeat

Jan 24, 2025

Jan 24, 2025

What is Wedbush's Estimate for TVTX FY2028 Earnings? - MarketBeat

Jan 24, 2025

Jan 24, 2025

TVTX Stock Soars to 52-Week High, Reaching $20.36 By Investing.com - Investing.com Australia

Jan 24, 2025

Jan 24, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Jan 24, 2025

Jan 24, 2025

Travere therapeutics CAO Calvin Sandra sells $17,520 in stock By Investing.com - Investing.com Canada

Jan 24, 2025

Jan 23, 2025

Travere therapeutics CFO sells shares worth $16,383 By Investing.com - Investing.com Australia

Jan 23, 2025

Jan 23, 2025

Travere therapeutics CAO Calvin Sandra sells $17,520 in stock - Investing.com

Jan 23, 2025

Jan 23, 2025

Travere therapeutics CEO Eric Dube sells shares for $208,922 By Investing.com - Investing.com South Africa

Jan 23, 2025

Jan 23, 2025

Travere therapeutics director Roy Baynes sells $320,000 in stock By Investing.com - Investing.com Canada

Jan 23, 2025

Jan 23, 2025

Travere therapeutics chief commercial officer sells $30,002 in stock By Investing.com - Investing.com Canada

Jan 23, 2025

Jan 23, 2025

Cantor Fitzgerald Predicts TVTX FY2025 Earnings - Defense World

Jan 23, 2025

Jan 23, 2025

FY2024 Earnings Estimate for TVTX Issued By Leerink Partnrs - Defense World

Jan 23, 2025

Jan 22, 2025

What is Leerink Partnrs' Estimate for TVTX FY2024 Earnings? - MarketBeat

Jan 22, 2025

Jan 22, 2025

Analysts Issue Forecasts for TVTX FY2025 Earnings - MarketBeat

Jan 22, 2025

Jan 22, 2025

What is Leerink Partnrs’ Estimate for TVTX FY2026 Earnings? - Defense World

Jan 22, 2025

Jan 21, 2025

FY2026 Earnings Estimate for TVTX Issued By Leerink Partnrs - MarketBeat

Jan 21, 2025

Jan 19, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - Defense World

Jan 19, 2025

Jan 18, 2025

Research Analysts Issue Forecasts for TVTX FY2024 Earnings - Defense World

Jan 18, 2025

Jan 17, 2025

HC Wainwright Issues Pessimistic Forecast for TVTX Earnings - MarketBeat

Jan 17, 2025

Jan 17, 2025

What is HC Wainwright’s Estimate for TVTX FY2029 Earnings? - Defense World

Jan 17, 2025

Jan 16, 2025

FY2029 Earnings Forecast for TVTX Issued By HC Wainwright - MarketBeat

Jan 16, 2025

Jan 15, 2025

Nephrotic Syndrome Market Set to Grow Substantially Through 2034, DelveInsight Projects | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squib - The Globe and Mail

Jan 15, 2025

Jan 15, 2025

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 at HC Wainwright - MarketBeat

Jan 15, 2025

Jan 14, 2025

Alport Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - Barchart

Jan 14, 2025

Jan 14, 2025

Alport Syndrome Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail

Jan 14, 2025

Jan 14, 2025

Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4.2%Here's Why - MarketBeat

Jan 14, 2025

Jan 13, 2025

Travere Therapeutics Provides Corporate Update and 2025 Outlook - The Manila Times

Jan 13, 2025

Jan 13, 2025

Travere's FILSPARI Drives $50M Q4 Sales, European Expansion Gains Momentum with Multi-Country Launch - StockTitan

Jan 13, 2025

Jan 12, 2025

Travere Therapeutics (NASDAQ:TVTX) Coverage Initiated at Cantor Fitzgerald - Defense World

Jan 12, 2025

Jan 11, 2025

Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56%: Here's is How to Trade - MSN

Jan 11, 2025